PPT-A NOVEL VSV-BASED EBOLA/HIV-1 VACCINE PROVIDES PROTECTION AGAINST SHIV IN MACAQUES

R4P 2021 Eric Arts on behalf of the VSVHIV vaccine team To work with Dr Chris Parks and IAVI to develop new VSVbased HIV vaccines that would propagate independent of VSV G andor HIV1 Env To design new HIV1 gp140 chimeras containing transmembrane and cytoplasmic tails from different viruses for optimal expression and antigen presentation on VSV particles. 573845744257452574555745557444573885737657462574555745357449574605738857376574565744557445573885737657456574555745557456573885737657459574635744557441574605738857376 VHPHQ5735957347VSLW5735957347RWKHU5734757536XLGV57356 Objects contaminated with the Pandemics and Emerging Infections. Sarah Gilbert, Jenner Institute, University of Oxford. THE JENNER INSTITUTE. a partnership between Oxford University and . the . Pirbright. Institute . - Developing innovative vaccines. Virus . Disease: treatment, gaps and options. Ellis Owusu-Dabo . (BSc, MB ChB. , MSc, PhD, MWACP, FGCP) . Director, . KCCR/KNUST, Kumasi. , . Ghana . www.kccr-ghana.org. . Established in . October 1997. Intrarectal. Challenge with SHIV109CP3. Martin Markowitz MD. Aaron Diamond AIDS Research Center. An affiliate of the Rockefeller University. New York, New York. USA. Conflict of Interest. Research grants. Where did they get it?. How do you get the virus? . The EBOLA Health Commissioner. The EBOLA Health Commissioner . Understand science of disease and its transmission. Interrupt the transmission of the virus. AAMC Briefing. Dr. Jim LeDuc. Director. Galveston National Laboratory. University of Texas Medical Branch. 13 October 2015. GNL Mission. The mission of the GNL is to assist the NIAID and the nation by conducting basic and applied research designed to improve the prevention, diagnosis and treatment of naturally emerging and purposefully disseminated infectious diseases.. “On Demand” Oral PrEP: Lessons Learned from Macaque Models National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention J. Gerardo García-Lerma Ph.D. Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA phase . 1 clinical trial in HIV-1 infected . patients. Escaich Sonia, . COO . BIOSANTECH . SA.. Tat is a virulence factor of HIV. Transactivator. of transcription (Tat) of HIV-1 is essential for the viral . 1protection investigationYongqun He1Zuoshuang Xiang1 Thomas Todd1 Melanie Courtot2 Ryan Brinkman2Jie Zheng3ChristianJ StoeckertJr3James Malone4Philippe Rocca-Serra4Susanna-Assunta Sansone4JenniferFost spread through direct contact (through broken skin or mucous membranes) with infected blood and body fluids . not spread through the air or by water. Individuals are only infectious when they have symptoms, which can appear up to 21 days after exposure. Archana Vidya Boopathy,. 1. Anurag Nekkalapudi,. 1. Bhawna Sharma,. 1. Sophie Schulha,. 2. . Raphaela. Wimmer,. 2. Debi Jin,. 1. Janette Sung,. 1. Jeffrey Murry,. 1. Mark Nagel,. 1. Brian Carr,. And Influenza Preparedness. Jimmy Guidry, MD - DHH. January 20, 2015. Agenda Topics. Ebola Status Update: What has changed in West Africa that impacts EVD planning for US?. First Responder Update. Flu Season Update. A case study of ‘best practices’ in community engagement. Ms . Maureen . Njue . Dr Patricia . Njuguna. KEMRI . Wellcome. Trust Research Programme, Kenya.. . Outline . KEMRI-Wellcome Trust, Kilifi . Fernandez-Garcia M, Majumdar M, Kebe O, Fall AD, Kone M, Kande M, et al. Emergence of Vaccine-Derived Polioviruses during Ebola Virus Disease Outbreak, Guinea, 2014–2015. Emerg Infect Dis. 2018;24(1):65-74. https://doi.org/10.3201/eid2401.171174.